Phrontline Biopharma Starts Phase I/II Trials for Dual-Payload ADC TJ102#China#Hangzhou#Phrontline_Biopharma#bispecific_ADC#TJ102
Phrontline Biopharma Starts Phase I/II Trials for Dual-Payload ADC TJ102
Phrontline Biopharma announces the start of its Phase I/II trial for TJ102, a bispecific ADC aimed at treating ovarian cancer and solid tumors.
third-news.com
September 30, 2026 at 2:18 PM
Phrontline Biopharma Starts Phase I/II Trials for Dual-Payload ADC TJ102#China#Hangzhou#Phrontline_Biopharma#bispecific_ADC#TJ102
Akeso's Breakthrough Bispecific ADC Receives NMPA Phase I Clearance for Solid Tumors#China#Hong_Kong#Akeso#bispecific_ADC#AK158D1
Akeso's Breakthrough Bispecific ADC Receives NMPA Phase I Clearance for Solid Tumors
Akeso Inc. announces that its bispecific antibody-drug conjugate AK158D1 has gained Phase I clearance in China for treating advanced tumors.
third-news.com
September 17, 2026 at 6:42 AM
Akeso's Breakthrough Bispecific ADC Receives NMPA Phase I Clearance for Solid Tumors#China#Hong_Kong#Akeso#bispecific_ADC#AK158D1
Akeso's Innovative Treatment Approach: First Patient Enters Phase II Trial for Advanced Breast Cancer Therapy#Hong_Kong#Akeso#Ivonescimab#bispecific_ADC
Akeso's Innovative Treatment Approach: First Patient Enters Phase II Trial for Advanced Breast Cancer Therapy
Akeso, Inc. has commenced a Phase II clinical study for breast cancer treatment, integrating its innovative bispecific antibodies and ADC strategy to enhance patient outcomes.
third-news.com
August 10, 2026 at 4:18 AM
Akeso's Innovative Treatment Approach: First Patient Enters Phase II Trial for Advanced Breast Cancer Therapy#Hong_Kong#Akeso#Ivonescimab#bispecific_ADC